Seroprevalence of IgG antibodies against hepatitis-A infection among individuals aged 6-30 years in India, 2021: a nationwide population-based cross-sectional study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumar Muthusamy Santhosh, Kumar Chethrapilly Purushothaman Girish, Saravanakumar Velusamy, Karunakaran Thiyagarajan, Vivian Thangaraj Jeromie Wesley, Selvaraju Sriram, Rade Kiran, Sabarinathan Ramasamy, Parvathi Surendran, Asthana Smita, Balachandar Rakesh, Bangar Sampada Dipak, Bansal Avi Kumar, Bhat Jyothi, Chakraborty Debjit, Chopra Vishal, Das Dasarathi, Devi Kangjam Rekha, Dwivedi Gaurav Raj, Salim Khan S Muhammad, Kumar M Sunil, Laxmaiah Avula, Madhukar Major, Mahapatra Amarendra, Ramesh Talluri, Rangaraju Chethana, Turuk Jyotirmayee, Yadav Suresh, Bhatnagar Tarun, Bhargava Balram, Murhekar Manoj V, ICMR serosurveillance group
Аннотация
METHODS: We used serum samples collected during the fourth national COVID-19 serosurvey conducted between 14 June and 6 July 2021 to estimate the seroprevalence of HAV infection. The survey was conducted in 70 randomly selected districts across 20 Indian states and one union territory. We tested the serum samples from individuals aged six to 30 years for IgG antibodies against HAV. We estimated the overall and state-specific seroprevalence, along with 95% CIs, for the age groups of 6-10, 11-15 and 16-30 years. We classified the HAV endemicity in India using WHO classification (high, intermediate, low and very low).
FINDINGS: We tested 14,778 serum samples from individuals aged six to 30 years for IgG antibodies against HAV. Of these, 12,236 (90.0%, 95% CI 88.5-91.4) were found to be reactive. The seroprevalence increased with age, from 74.7% (71.1-77.9) among children aged 6-10 years to 85.2% (82.7-87.4) among those aged 11-15 years and 96.9% (96.3-97.5) among individuals aged 16-30 years. India was categorized as having intermediate endemicity for HAV infection as per the WHO classification. Of the 21 states or union territories included in the survey, 18 had intermediate endemicity.
INTERPRETATION: Our study findings indicate an intermediate level of endemicity for HAV infection in India. While these findings support consideration of hepatitis-A vaccination, further evidence on disease burden and cost-effectiveness is needed to inform policy decisions.
FUNDING: Gates Foundation & Indian Council of Medical Research.